Ultragenyx outlines 2027 profitability plan with R&D under $350M and SG&A under $375M following GTX-102 discontinuation

Earnings Call Insights: Ultragenyx Pharmaceutical Inc. (RARE) Q3 2026

Management View

• CEO Emil Kakkis framed Q3 as marked by two FDA approvals and two major pipeline exits: "In August and September, the FDA approved GENGLYCOS for Glycogen storage disease type Ia and

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.